Human cutaneous leishmaniasis: interferon-dependent expression of double-stranded RNA-dependent protein kinase (PKR) via TLR2

Carregando...
Imagem de Miniatura
Citações na Scopus
49
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
FEDERATION AMER SOC EXP BIOL
Autores
VIVARINI, Aislan de Carvalho
PEREIRA, Renata de Meirelles Santos
TEIXEIRA, Karina Luiza Dias
CALEGARI-SILVA, Teresa Cristina
BELLIO, Maria
SOARES, Rodrigo Pedro
SILVA, Aristobolo Mendes
Citação
FASEB JOURNAL, v.25, n.12, p.4162-4173, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We investigated the type I interferon (IFN-1)/PKR axis in the outcome of the Leishmania (Leishmania) amazonensis infection, along with the underlying mechanisms that trigger and sustain this signaling pathway. Reporter assays of cell extracts from RAW-264.7 macrophages infected with L. (L.) amazonensis or HEK-293T cells cotransfected with TLR2 and PKR promoter constructions were employed. Primary macrophages of TLR2-knockout (KO) or IFNR-KO mice were infected, and the levels of PKR, IFN-1, and superoxide dismutase 1 (SOD1) transcript levels were investigated and compared. Immunohistochemical analysis of human biopsy lesions was evaluated for IFN-1 and PKR-positive cells. Leishmania infection increased the expression of PKR and IFN-beta on induction of PKR-promoter activity. The observed effects required the engagement of TLR2. TLR2-KO macrophages expressed low IFN-beta and PKR levels postinfection with a reduced parasite load. We also revealed the requirement of PKR signaling for Leishmania-induced IFN-1 expression, responsible for sustaining PKR expression and enhancing infection. Moreover, during infection, SOD1 transcripts increased and were also enhanced when IFN-1 was added to the cultures. Remarkably, SOD1 expression was abrogated in infected, dominant-negative PKR-expressing cells. Finally, lesions of patients with anergic diffuse cutaneous leishmaniasis exhibited higher levels of PKR/IFN1-expressing cells compared to those with single cutaneous leishmaniasis. In summary, we demonstrated the mechanisms and relevance of the IFN-1/PKR axis in the Leishmania infection.-De Carvalho Vivarini, A., Pereira, R. M. S., Dias Teixeira, K. L., Calegari-Silva, T. C., Bellio, M., Laurenti, M. D., Corbett, C. E. P., de Castro Gomes, C. M., Soares, R. P., Mendes Silva, A., Silveira, F. T., Lopes, U. G. Human cutaneous leish-maniasis: interferon-dependent expression of double-stranded RNA-kinase (PKR) via TLR2. FASEB J. 25, 4162-4173 (2011). www.fasebj.org
Palavras-chave
interferon-1, Toll-like receptor 2, SOD1
Referências
  1. Akuffo H, 1997, J INFECT DIS, V175, P737
  2. Khouri R, 2009, J IMMUNOL, V182, P2525, DOI 10.4049/jimmunol.0802860
  3. Das S, 2006, J BIOL CHEM, V281, P3244, DOI 10.1074/jbc.M510612200
  4. Cohen-Chalamish S, 2009, NAT CHEM BIOL, V5, P896, DOI 10.1038/nchembio.234
  5. Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772
  6. de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128
  7. Hsu LC, 2004, NATURE, V428, P341, DOI 10.1038/nature02405
  8. Silveira FT, 2009, PARASITE IMMUNOL, V31, P423, DOI 10.1111/j.1365-3024.2009.01116.x
  9. Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001
  10. Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5
  11. Perry AK, 2005, CELL RES, V15, P407, DOI 10.1038/sj.cr.7290309
  12. Ives A, 2011, SCIENCE, V331, P775, DOI 10.1126/science.1199326
  13. Barbalat R, 2009, NAT IMMUNOL, V10, P1200, DOI 10.1038/ni.1792
  14. Chai Y, 2011, MOL BIOL REP, V38, P139, DOI 10.1007/s11033-010-0087-1
  15. Pindel A, 2011, J INTERF CYTOK RES, V31, P59, DOI 10.1089/jir.2010.0099
  16. Lykens JE, 2010, J IMMUNOL, V184, P877, DOI 10.4049/jimmunol.0902346
  17. Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783
  18. Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200
  19. Cabanski M, 2008, AM J RESP CELL MOL, V38, P26, DOI 10.1165/rcmb.2007-0010OC
  20. Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4
  21. Gregory DJ, 2005, PARASITOLOGY, V130, pS27, DOI 10.1017/S0031182005008139
  22. Schulz O, 2010, CELL HOST MICROBE, V7, P354, DOI 10.1016/j.chom.2010.04.007
  23. Kamhawi S, 2004, CELL, V119, P329, DOI 10.1016/j.cell.2004.10.009
  24. Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127
  25. Becker I, 2003, MOL BIOCHEM PARASIT, V130, P65, DOI 10.1016/S0166-6851(03)00160-9
  26. Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
  27. Mattner J, 2004, J IMMUNOL, V172, P7574
  28. Pereira RMS, 2010, FASEB J, V24, P617, DOI 10.1096/fj.09-140053
  29. Bonfim G., 1996, EXP PARASITOL, V84, P188
  30. Brittingham A, 1996, PARASITOL TODAY, V12, P444, DOI 10.1016/0169-4758(96)10067-3
  31. Cheung BKW, 2005, J IMMUNOL, V175, P7218
  32. Dietrich N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010250
  33. Giorgione JR, 1996, P NATL ACAD SCI USA, V93, P11634, DOI 10.1073/pnas.93.21.11634
  34. Khouri R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014394
  35. Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536
  36. Mattner J, 2000, EUR J IMMUNOL, V30, P2257, DOI 10.1002/1521-4141(2000)30:8<2257::AID-IMMU2257>3.0.CO;2-U
  37. Schriefer A, 2008, CURR OPIN INFECT DIS, V21, P483, DOI 10.1097/QCO.0b013e32830d0ee8
  38. Shankar AH, 1996, EXP PARASITOL, V84, P136, DOI 10.1006/expr.1996.0099
  39. Silveira FT, 1998, PARASITE IMMUNOL, V20, P19, DOI 10.1046/j.1365-3024.1998.t01-1-00126.x
  40. Soares RPP, 2002, MOL BIOCHEM PARASIT, V121, P213, DOI 10.1016/S0166-6851(02)00033-6
  41. Vargas-Inchaustegui DA, 2009, INFECT IMMUN, V77, P2948, DOI 10.1128/IAI.00154-09
  42. Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356
  43. *WHO, 2010, LEISHM BURD DIS
  44. Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2
  45. Wilson J, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000179